SEC Tracker
Get the app

Dare Bioscience DARE

Dare Bioscience Q3 FY23: revenue $1.0M; diluted EPS −$1.08

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Dare Bioscience reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$8.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$1.08No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.0910-Q income statement, on EDGAR
  4. Cash and cash equivalents$13.9MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$8.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Dare Bioscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  2. Imunon IMNN public float $21M, Jun 30, 2025
  3. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  4. Fibrogen FGEN public float $21M, Jun 30, 2025
  5. Aptose Biosciences APTOF public float $22M, Jun 28, 2025

Data on this page was fetched . The filing on SEC.gov is the record.